Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib for HES, PV, Atypical CML/CMML, and Mastocytosis
NCT00038675Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2001
- Primary completion
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of imatinib in hypereosinophilic syndrome (HES), polycythemia vera (PV), Atypical chronic myeloid leukemia (aCML), chronic myelomonocytic leukemia (CMML), mastocytosis, sponsored by University of Texas MD Anderson Cancer Center. Started Jun 2001; status: completed.
02
Drugs
03
Conditions
hypereosinophilic syndrome (HES)polycythemia vera (PV)Atypical chronic myeloid leukemia (aCML)chronic myelomonocytic leukemia (CMML)mastocytosis
Beyond the preview
Go deeper on NCT00038675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00038675.